Skip to main content

Table 3 Association between clinician-rated ECOG-PS ratings and the participant-reported quality of life within the EQ-5D-5 L domains

From: Defining the relationship between clinician-rated ECOG performance status and patient-reported health-related quality of life scores in men with metastatic hormone-naïve prostate cancer

EQ-5D-5 L Dimensions

 

ECOG 1 (n = 51)

ECOG 2 (n = 125)

ECOG 3 (n = 47)

Total (n = 223)

Test of Significance

 

5

0

0

2 (4.3%)

2 (0.9%)

 
 

4

0

12 (9.6%)

13 (27.7%)

25 (11.2%)

 

Mobility

3

6 (11.8%)

38 (30.4%)

18 (38.3%)

62 (27.8%)

χ2=63.19; π<0.001

 

2

26 (51.0%)

64 (51.2%)

13 (27.7%)

103 (46.2%)

 
 

1

19 (37.3%)

11 (8.8%)

1 (2.1%)

31 (13.9%)

 
 

5

0

0

1 (2.1%)

1 (0.4%)

 
 

4

1 (2.0%)

4 (3.2%)

12 (25.5%)

17 (7.6%)

 

Self-Care

3

3 (5.9%)

21 (16.8%)

13 (27.7%)

37 (16.6%)

χ2=56.68; π<0.001

 

2

25 (49.0%)

76 (60.85)

19 40.4%)

120 (53.8%)

 
 

1

22 (43.1%)

24 (19.2%)

2 (4.3%)

48 (21.5%)

 
 

5

0

0

1 (2.1%)

1 (0.4%)

 
 

4

1 (2.0%)

9 (7.2%)

13 (27.7%)

23 (10.3%)

 

Usual Activities

3

8 (15.7%)

59 (47.2%)

24 (51.1%)

91 (40.8%)

χ2=53.55; π<0.001

 

2

38 (74.5%)

52 (41.6%)

9 (19.1%)

99 (44.4%)

 
 

1

4 (7.8%)

5 (4.0%)

0

9 (4.0%)

 
 

5

0

3 (2.4%)

1 (2.1%)

4 (1.8%)

 
 

4

1 (2.0%)

11 (8.8%)

17 (36.2%)

29 (13.0%)

 

Pain/Discomfort

3

22 (43.1%)

68 (54.4%)

26 (55.3%)

116 (52.0%)

χ2=51.73; π<0.001

 

2

19 (37.3%)

38 (30.4%)

2 (4.3%)

59 (26.5%)

 
 

1

9 (17.6%)

5 (4.0%)

1 (2.1%)

15 (6.7%)

 
 

5

0

0

0

0

 
 

4

0

3 (2.4%)

2 (4.2%)

5 (2.2%)

 

Anxiety/Depression

3

1 (2.0%)

11 (8.8%)

12 (25.5%)

24 (10.8%)

χ2=20.75; π=0.002

 

2

27 (52.9%)

69 (55.2%)

24 (51.1%)

120 (53.8%)

 
 

1

23 (45.1%)

42 (33.6%)

9 (19.1%)

74 (33.2%)

 
  1. [ECOG: Eastern Cooperative Oncology Group]